Overview

Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants

Status:
Completed
Trial end date:
2021-05-21
Target enrollment:
Participant gender:
Summary
Primary Objective: - To evaluate the impact of food on the pharmacokinetics (PK) of rilzabrutinib following single oral doses to healthy subjects. - To evaluate the impact of formulation on the PK of rilzabrutinib following single oral doses to healthy subjects Secondary Objective: - To assess the safety and tolerability of single oral doses of rilzabrutinib administered under fasted and fed conditions
Phase:
Phase 1
Details
Lead Sponsor:
Principia Biopharma, a Sanofi Company
Sanofi